Skip to main content

Table 1 Demographics of subjects undergoing treatment with the ExAblate 2000 and 2100 systems

From: Safety and treatment volumes achieved following new developments of the magnetic resonance-guided focused ultrasound system in the treatment of uterine fibroids: a cohort study

  ExAblate 2000 (n = 238) ExAblate 2100 (n = 34) p Value
Age Mean years (range) 42.2 (25–84) 39.47 (25–52) 0.26a
BMI Mean (SD) 25.1 (4.6) 23.41 (3.79) 0.038a
Race White, N (%) 135 (48.0) 14 (41.18) 0.01b
Black, N (%) 76 (27.0) 12 (35.30) 0.01b
Asian, N (%) 18 (6.4) 8 (23.52) 0.01b
Arabic, N (%) 7 (2.5) 0 0.01b
Mixed, N (%) 4 (1.4) 0 0.01b
Parity Mean (SD) 0.51 (0.89) 0.38 (0.82) 0.328c
Symptom severity score Mean (SD) 62.64 (17.80) 61.71 (17.86) 0.841c
Hyper-intense fibroids N (%) 67 (28.2) 6 (17.6) 0.196b
Previous treatment N (%) 43 (15.4) 5 (13.9) 0.88b
Number of fibroids Mean (SD) 6.43 (6.54) 4.18 (3.85) 0.044c
Mean uterine volume ml (SD) 788.12 (408.01) 659.62 (259.91) 0.093c
  1. BMI body mass index.
  2. aTwo-tailed t test.
  3. bChi-square test.
  4. cMann-Whitney test.